In-depth interviews of non-hepatologists and the achievements made after introducing a "patient referral document for hepatitis" in our hospital

Takako Inoue(Kaneka (United States)), Yasuhito Tanaka(Kumamoto University), Tomomitsu Matono(Tottori University), Shunsuke Nojiri(Nagoya City University), Kei Fujiwara(Nagoya City University), Koichi Honda(Yamagata University), Etsuko Iio(Nagoya City University), Masaru Enomoto(Osaka City University), Kentaro Matsuura(Nagoya City University), Masaaki Korenaga(National Center for Global Health and Medicine), Jun Inoue(Tohoku University), Kayoko Matsunami(Nagoya City University), Yasuteru Kondo(Sendai Kousei Hospital)
Kanzo
July 1, 2019
10.2957/kanzo.60.219
Cited by 1

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis
|Hepatology|2006|365
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP)
|Hepatology|2013|259
Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
|Proceedings of the National Academy of Sciences|2019|241